Abstract Objective To determine serum levels of resistin and visfatin in the patients with acute Kawasaki disease before and after intravenous immune globulin (IVIG) treatment. Methods A total of 50 children with acute Kawasaki disease were treated with IVIG for 48 hours between January 2011 and January 2013. As controls, 30 healthy children and 30 children with acute infectious diseases were included. Serum levels of resistin and visfatin were measured by ELISA both before and after the treatment. Results The baseline serum levels of resistin and visfatin were significantly higher in patients with acute Kawasaki disease than in the two control groups of subjects (i.e., healthy children and patients with acute infectious diseases; P<0.05). In the 50 patients with Kawasaki disease, 38 were not responding and 12 were responding. Serum resistin levels before treatment were significantly higher in non-responders than those in responders (P<0.05). A significant decrease in serum levels of resistin after treatment was observed in IVIG responders (P<0.05). Serum visfatin levels were not significantly different between IVIG responders and non-responders (P >0.05). Additionally, serum resistin and visfatin levels were not significantly different between acute Kawasaki disease patients with and without coronary artery lesions. Conclusions Resistin and visfatin may play important roles in the development of Kawasaki disease and serum resistin may be used as a novel outcome indicator of the IVIG treatment.
FU Shu-Fang,YU Da-Liang,LV Dian-Yi et al. Changes in serum levels of resistin and visfatin in pediatric patients with acute Kawasaki disease following intravenous immune globulin treatment[J]. CJCP, 2014, 16(1): 44-47.
FU Shu-Fang,YU Da-Liang,LV Dian-Yi et al. Changes in serum levels of resistin and visfatin in pediatric patients with acute Kawasaki disease following intravenous immune globulin treatment[J]. CJCP, 2014, 16(1): 44-47.
Ayusawa M, Sonobe T, Uemura S, et al. Revision of diagnostic guidelines for Kawasaki disease(the 5th revisededition)[J]. Pediatrint, 2005, 47(2): 232-234.
[2]
Kowalczyk M, Turska-Kmiec A, Ziolkowska L, et al. Symptoms, diagnosis and characteristic abnormalities in the coronary arteries in Kawasaki disease in children[J]. Med Wieku Rozwoj, 2010, 14(4): 344-349.
Takahashi K, Oharaseki T, Yokouchi Y. Pathogenesis of Kawasaki disease[J]. Clin Exp Immunol, 2011, 164 Suppl 1: 20-22.
[7]
Kakizaki S, Sohara N, Yamazaki Y, et al. Elevated plasma resistin concentrations in patients with liver cirrhosis[J]. J Gastroenterol Hepatol, 2008, 23(1): 73-77.
[8]
Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction[J]. Circulation, 2003, 108(6): 736-740.
Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin[J]. Science, 2005, 307(5708): 426-430.
[11]
Li RZ, Ma Xn, Hu XF, et al. Elevated visfatin levels in obese children are related to proinflammatory factors[J]. J Pediatr Endocrinol Metab, 2013, 26(1-2): 111-118.
[12]
Jia SH, Li Y, Parodo J, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis[J]. J Clin Invest, 2004, 113(9): 1318-1327.
